title: Acute renal failure under dasatinib therapy.
abstract: Dasatinib is a second-generation tyrosine kinase inhibitor that is approved for the treatment of imatinib-resistant or imatinib-intolerant chronic myeloid leukemia. It has a 325 times stronger in vitro activity against to native BCR-ABL when comparing with imatinib. Little is known about the effects of dasatinib on renal function. A literature review revealed only one case with imatinib-resistant chronic myeloid leukemia that developed renal failure after being placed on dasatinib therapy. Here we report a patient with imatinib-resistant chronic myeloid leukemia who developed gastroenteritis and acute renal failure after a short time from the initiation of dasatinib therapy. After dasatinib interruption, these side effects resolved completely in days. In summary, dasatinib is a potent drug in the treatment of chronic myeloid leukemia, but close clinical monitoring and the timely interruption of the therapy in patients who developed acute renal failure are warranted.
authors.affiliation: Department of Nephrology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey.
authors.forename: Sultan
authors.initials: S
authors.lastname: Ozkurt
authors.forename: Gokhan
authors.initials: G
authors.lastname: Temiz
authors.forename: Mustafa Fuat
authors.initials: MF
authors.lastname: Acikalin
authors.forename: Mehmet
authors.initials: M
authors.lastname: Soydan
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D000069439:Dasatinib; D005260:Female; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib